21 related articles for article (PubMed ID: 38740809)
1. A bicentric retrospective study of the correlation of EAU BCR risk groups with
Poterszman N; Merlin C; Margail C; Ouvrard E; Imperiale A; Somme F
Sci Rep; 2024 May; 14(1):10908. PubMed ID: 38740809
[TBL] [Abstract][Full Text] [Related]
2. EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer.
Falkenbach F; Ambrosini F; Tennstedt P; Eiber M; Heck MM; Preisser F; Graefen M; Budäus L; Koehler D; Knipper S; Maurer T
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894375
[TBL] [Abstract][Full Text] [Related]
3. European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study.
Preisser F; Abrams-Pompe RS; Stelwagen PJ; Böhmer D; Zattoni F; Magli A; Rivas JG; Dilme RV; Sepulcri M; Eguibar A; Heidegger I; Arnold C; Fankhauser CD; Chun FK; van der Poel H; Gandaglia G; Wiegel T; van den Bergh RCN; Tilki D;
Eur Urol; 2024 Feb; 85(2):164-170. PubMed ID: 37355358
[TBL] [Abstract][Full Text] [Related]
4. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).
Seifert R; Emmett L; Rowe SP; Herrmann K; Hadaschik B; Calais J; Giesel FL; Reiter R; Maurer T; Heck M; Gafita A; Morris MJ; Fanti S; Weber WA; Hope TA; Hofman MS; Fendler WP; Eiber M
Eur Urol; 2023 May; 83(5):405-412. PubMed ID: 36935345
[TBL] [Abstract][Full Text] [Related]
5. [
Evangelista L; Maurer T; van der Poel H; Alongi F; Kunikowska J; Laudicella R; Fanti S; Hofman MS
Eur Urol Oncol; 2022 Jun; 5(3):273-282. PubMed ID: 35367165
[TBL] [Abstract][Full Text] [Related]
6. Risk of metastatic disease using [
Chikatamarla VA; Okano S; Jenvey P; Ansaldo A; Roberts MJ; Ramsay SC; Thomas PA; Pattison DA
EJNMMI Res; 2021 Dec; 11(1):128. PubMed ID: 34928437
[TBL] [Abstract][Full Text] [Related]
7. PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study.
Ferdinandus J; Fendler WP; Farolfi A; Washington S; Mohamad O; Pampaloni MH; Scott PJH; Rodnick M; Viglianti BL; Eiber M; Herrmann K; Czernin J; Armstrong WR; Calais J; Hope TA; Piert M
J Nucl Med; 2022 Jan; 63(1):76-80. PubMed ID: 34620731
[TBL] [Abstract][Full Text] [Related]
8. The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.
Dong L; Su Y; Zhu Y; Markowski MC; Xin M; Gorin MA; Dong B; Pan J; Pomper MG; Liu J; Pienta KJ; Xue W; Rowe SP
J Nucl Med; 2022 Feb; 63(2):248-252. PubMed ID: 34326128
[TBL] [Abstract][Full Text] [Related]
9. Focal unspecific bone uptake on [
Grünig H; Maurer A; Thali Y; Kovacs Z; Strobel K; Burger IA; Müller J
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4483-4494. PubMed ID: 34120201
[TBL] [Abstract][Full Text] [Related]
10. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.
Ceci F; Oprea-Lager DE; Emmett L; Adam JA; Bomanji J; Czernin J; Eiber M; Haberkorn U; Hofman MS; Hope TA; Kumar R; Rowe SP; Schwarzenboeck SM; Fanti S; Herrmann K
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1626-1638. PubMed ID: 33604691
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.
Vale CL; Fisher D; Kneebone A; Parker C; Pearse M; Richaud P; Sargos P; Sydes MR; Brawley C; Brihoum M; Brown C; Chabaud S; Cook A; Forcat S; Fraser-Browne C; Latorzeff I; Parmar MKB; Tierney JF;
Lancet; 2020 Oct; 396(10260):1422-1431. PubMed ID: 33002431
[TBL] [Abstract][Full Text] [Related]
12. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma.
van Leenders GJLH; van der Kwast TH; Grignon DJ; Evans AJ; Kristiansen G; Kweldam CF; Litjens G; McKenney JK; Melamed J; Mottet N; Paner GP; Samaratunga H; Schoots IG; Simko JP; Tsuzuki T; Varma M; Warren AY; Wheeler TM; Williamson SR; Iczkowski KA;
Am J Surg Pathol; 2020 Aug; 44(8):e87-e99. PubMed ID: 32459716
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.
Van den Broeck T; van den Bergh RCN; Arfi N; Gross T; Moris L; Briers E; Cumberbatch M; De Santis M; Tilki D; Fanti S; Fossati N; Gillessen S; Grummet JP; Henry AM; Lardas M; Liew M; Rouvière O; Pecanka J; Mason MD; Schoots IG; van Der Kwast TH; van Der Poel HG; Wiegel T; Willemse PM; Yuan Y; Lam TB; Cornford P; Mottet N
Eur Urol; 2019 Jun; 75(6):967-987. PubMed ID: 30342843
[TBL] [Abstract][Full Text] [Related]
14. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.
Giesel FL; Hadaschik B; Cardinale J; Radtke J; Vinsensia M; Lehnert W; Kesch C; Tolstov Y; Singer S; Grabe N; Duensing S; Schäfer M; Neels OC; Mier W; Haberkorn U; Kopka K; Kratochwil C
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):678-688. PubMed ID: 27889802
[TBL] [Abstract][Full Text] [Related]
15. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
16. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen.
Freedland SJ; Sutter ME; Dorey F; Aronson WJ
Urology; 2003 Feb; 61(2):365-9. PubMed ID: 12597949
[TBL] [Abstract][Full Text] [Related]
17. Natural history of progression after PSA elevation following radical prostatectomy.
Pound CR; Partin AW; Eisenberger MA; Chan DW; Pearson JD; Walsh PC
JAMA; 1999 May; 281(17):1591-7. PubMed ID: 10235151
[TBL] [Abstract][Full Text] [Related]
18. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.
Gleason DF; Mellinger GT
J Urol; 1974 Jan; 111(1):58-64. PubMed ID: 4813554
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
